Viking Therapeutics Inc
NASDAQ:VKTX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11.72
94.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Viking Therapeutics Inc
Wall Street
Price Targets
VKTX Price Targets Summary
Viking Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
VKTX
is 119.71 USD
with a low forecast of 95.95 USD and a high forecast of 172.2 USD.
VKTX Last Price Targets
Viking Therapeutics Inc
The latest public price target was made on Nov 4, 2024 by
Yale Jen
from
Laidlaw
,
who expects
VKTX
stock to
rise by 109%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Yale Jen
Laidlaw
|
110
USD
Upside 109% |
2 weeks ago
Nov 4, 2024
|
Laidlaw Reiterates Buy Rating on Viking Therapeutic (VKTX)
StreetInsider
|
Roger Song
Jefferies
|
110
USD
Upside 109% |
2 weeks ago
Nov 4, 2024
|
Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX)
StreetInsider
|
Michael Ulz
Morgan Stanley
|
105
USD
Upside 100% |
4 months ago
Jun 27, 2024
|
Viking Therapeutics initiated with an Overweight at Morgan Stanley
TheFly
|
|
Joseph Pantginis
H.C. Wainwright
|
90
USD
Upside 71% |
4 months ago
Jun 25, 2024
|
H.C. Wainwright Reiterates Buy Rating on Viking Therapeutic (VKTX)
StreetInsider
|
Joon Lee
Truist Financial
|
120
USD
Upside 128% |
6 months ago
May 16, 2024
|
Roche data falls short of Viking weight loss drug, says Truist
TheFly
|
Steve Seedhouse
Raymond James
|
116
USD
Upside 121% |
6 months ago
May 16, 2024
|
Raymond James Upgrades Viking Therapeutic (VKTX) to Strong Buy
StreetInsider
|
Jay Olson
Oppenheimer
|
138
USD
Upside 162% |
7 months ago
Mar 26, 2024
|
Viking Therapeutic (VKTX) PT Raised to $138 at Oppenheimer
StreetInsider
|
|
Justin Zelin
BTIG
|
125
USD
Upside 138% |
7 months ago
Mar 26, 2024
|
Viking Therapeutic (VKTX) PT Raised to $125 at BTIG
StreetInsider
|
Samimy Annabel
Stifel Nicolaus
|
95
USD
Upside 81% |
7 months ago
Mar 26, 2024
|
Viking Therapeutic (VKTX) PT Raised to $95 at Stifel
StreetInsider
|
|
Justin Zelin
BTIG
|
100
USD
Upside 90% |
8 months ago
Mar 15, 2024
|
Viking Therapeutic (VKTX) PT Raised to $100 at BTIG
StreetInsider
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is VKTX's stock price target?
Price Target
119.71
USD
According to Wall Street analysts, the average 1-year price target for
VKTX
is 119.71 USD
with a low forecast of 95.95 USD and a high forecast of 172.2 USD.
You don't have any saved screeners yet
